GRALAnother day, another lawyer letter
Grail just got itself a new headache. Levi & Korsinsky says it’s investigating whether the company’s guidance around cash runway and burn rate painted too rosy a picture before the NHS Galleri randomized trial fell flat on its primary endpoint.
Why investors are squinting at this
The complaint isn’t about the company saying it had cash. It’s about whether management’s “we’re good into 2030” vibe assumed a clean clinical path that, in reality, wasn’t so clean.
According to the write-up, CEO Robert P. Ragusa said on the November 12, 2025 Q3 call that Grail’s runway extended into 2030, while CFO Aaron Freidin said 2025 cash burn would be no more than $290 million. The problem, at least in the plaintiffs’ telling, is that those numbers didn’t account for the possibility that the NHS trial would miss its primary endpoint.
The market already did the math
When that trial outcome was disclosed in February 2026, the stock reportedly dropped about 50%. So even if this reads like the usual pre-lawsuit starter pack, the market reaction suggests investors think the trial miss was not exactly a rounding error.
Big picture: Grail doesn’t just have a science problem here — it may also have a credibility problem, and Wall Street tends to charge extra for both.